TG Therapeutics' strong cash position and Briumvi success fuel growth potential. Find out why TGTX stock is rated a strong ...

A once-yearly intramuscular lenacapavir (Sunlenca) injection was safe and well-tolerated and had higher median levels of ...

For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I ...

An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...

Pre-exposure prophylaxis (PrEP) is the advent of antiretroviral treatment use for people at increased risk of acquiring HIV-1 ...

UD researchers discover that differences in gene expression in fat could be the key to targeted obesity treatment. According ...

Viking Therapeutics (VKTX) announced that it has signed a broad, multi-year manufacturing agreement with CordenPharma, a contract development ...